Issue Date: February 7, 2011
Valeant to acquire Swiss Generics Firm
In a bid to strengthen its position in Central and Eastern Europe, Valeant Pharmaceuticals (formerly Biovail) will pay $480 million for privately owned over-the-counter and generic drug firm PharmaSwiss. Last year, PharmaSwiss posted about $250 million in sales, a level that has been growing roughly 20% annually. Biovail took the Valeant name last fall after its $3.3 billion acquisition of that firm.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society